<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PlatCOVID</title>
    <link>/drugpanel/glutathione/</link>
      <atom:link href="/drugpanel/glutathione/index.xml" rel="self" type="application/rss+xml" />
    <description>PlatCOVID</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png</url>
      <title>PlatCOVID</title>
      <link>/drugpanel/glutathione/</link>
    </image>
    
    <item>
      <title>GLUTATHIONE</title>
      <link>/drugpanel/glutathione/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/drugpanel/glutathione/info/</guid>
      <description>
&lt;script src=&#34;/rmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p align=&#34;left&#34; style=&#34;font-size:16px&#34;&gt;
DrugBank ID: &lt;a href=&#39;https://www.drugbank.ca/drugs/db00143&#39; target=&#39;_blank&#39;&gt;db00143&lt;/a&gt; &lt;br&gt;
DrugCentral: &lt;a href=&#34;http://drugcentral.org/?q=date&#34; target=&#34;_blank&#34;&gt;date&lt;/a&gt; &lt;br&gt;
Synonymous :5-l-glutamyl-l-cysteinylglycine | gamma-l-glutamyl-l-cysteinyl-glycine | glutathione | glutathione-sh | gsh | n-(n-gamma-l-glutamyl-l-cysteinyl)glycine | reduced glutathione
&lt;/p&gt;
&lt;p&gt;&lt;br&gt;&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;drug-sentece-context&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Drug Sentece Context&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; Analysis of context sentence of &lt;em&gt;date&lt;/em&gt; gene in 343 abstracts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
pmid
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
sentence
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/publication/32322478&#34; target=&#34;_blank&#34;&gt;32322478&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We evaluated the effects of using high dose oral and/or IV glutathione in the treatment of 2 patients with dyspnea secondary to COVID-19 pneumonia. […] A trial of 2 g of PO or IV glutathione was used in both patients and improved their dyspnea within 1 h of use. […] Repeated use of both 2000 mg of PO and IV glutathione was effective in further relieving respiratory symptoms. […] Oral and IV glutathione, glutathione precursors (N-acetyl-cysteine) and alpha lipoic acid may represent a novel treatment approach for blocking NFKappaB and addressing “cytokine storm syndrome” and respiratory distress in patients with COVID-19 pneumonia.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/publication/32463221&#34; target=&#34;_blank&#34;&gt;32463221&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this Viewpoint is to justify (1) the crucial roles of glutathione in determining individual responsiveness to COVID-19 infection and disease pathogenesis and (2) the feasibility of using glutathione as a means for the treatment and prevention of COVID-19 illness. […] The hypothesis that glutathione deficiency is the most plausible explanation for serious manifestation and death in COVID-19 patients was proposed on the basis of an exhaustive literature analysis and observations.
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
